drugset / Trial / NCT06434090
Liposomal Irinotecan Plus Bevacizumab in Irinotecan-refractory Metastatic Colorectal Cancer
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of liposomal irinotecan plus bevacizumab in irinotecan-refractory metastatic colorectal cancer
Timeline
- Start
- 2024-06-05
- Primary completion
- 2025-06-05
- Completion
- 2026-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 5 mg/m2 | — |
| Subject | Irinotecan | Small molecule | 70 mg/m2 | — |
| Subject | Irinotecan | Small molecule | 80 mg/m2 | — |
| Subject | Irinotecan | Small molecule | 90 mg/m2 | — |